For Protein Degraders To Tackle Neurodegenerative Diseases, These Are The Barriers They Need To Overcome

Targeted protein degraders show great potential for treating neurodegenerative diseases like Alzheimer's and Parkinson's by removing harmful proteins. Unlike current drugs that often only manage symptoms, these therapies could fundamentally alter disease progression. However, developing protein degraders, specifically PROTACs, to work effectively in the brain is challenging. They must overcome significant obstacles, including crossing the blood-brain barrier, entering nerve cells, and being suitable for oral administration.

These are critical hurdles for this promising new class of drugs. Access the full article to learn more about these key barriers.